Literature DB >> 16140458

Liver protein synthesis stays elevated after chemotherapy in tumour-bearing mice.

Sue E Samuels1, Teresa A McLaren, Andrew L Knowles, Sarah A Stewart, Jean-Claude Madelmont, Didier Attaix.   

Abstract

We studied the effect of chemotherapy on liver protein synthesis in mice bearing colon 26 adenocarcinoma (C26). Liver protein mass decreased (-32%; P<0.05) in cachectic mice, but protein synthesis increased (20-35%; P<0.05) in cachectic mice, which is consistent with increased export protein synthesis. Increased protein synthesis in tumour-bearing mice was primarily mediated by increasing ( approximately 15%; P<0.05) the RNA concentration, i.e. the capacity for protein synthesis (Cs; mg RNA/g protein). Cystemustine, a nitrosourea chemotherapy that cures C26 with 100% efficacy, rapidly restored liver protein mass; protein synthesis however stayed higher than in healthy mice ( approximately 15%) throughout the initial and later stages of recovery. Chemotherapy had no significant effect on liver protein mass and synthesis in healthy mice. Reduced food intake was not a factor in this model. These data suggest a high priority for liver protein synthesis during cancer cachexia and recovery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140458     DOI: 10.1016/j.canlet.2005.07.026

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

1.  The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia.

Authors:  Andrea Bonetto; Joseph E Rupert; Rafael Barreto; Teresa A Zimmers
Journal:  J Vis Exp       Date:  2016-11-30       Impact factor: 1.355

2.  Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.

Authors:  Paola Aulino; Emanuele Berardi; Veronica M Cardillo; Emanuele Rizzuto; Barbara Perniconi; Carla Ramina; Fabrizio Padula; Enrico P Spugnini; Alfonso Baldi; Fabio Faiola; Sergio Adamo; Dario Coletti
Journal:  BMC Cancer       Date:  2010-07-08       Impact factor: 4.430

Review 3.  Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments.

Authors:  Juha J Hulmi; Tuuli A Nissinen; Fabio Penna; Andrea Bonetto
Journal:  Cells       Date:  2021-02-28       Impact factor: 6.600

4.  Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.

Authors:  Tuuli A Nissinen; Jaakko Hentilä; Fabio Penna; Anita Lampinen; Juulia H Lautaoja; Vasco Fachada; Tanja Holopainen; Olli Ritvos; Riikka Kivelä; Juha J Hulmi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-05-02       Impact factor: 12.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.